New MRI dye could sharpen prostate cancer detection
NCT ID NCT06226129
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tests a new contrast agent called Gadopiclenol (Elucirem) to see if it improves MRI scans for finding aggressive prostate cancer. About 150 men scheduled for a prostate MRI with contrast will receive this agent. The goal is to see if it provides clearer images and better distinguishes dangerous cancers from harmless ones.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact
Conditions
Explore the condition pages connected to this study.